SCHEMBL6647166

SCHEMBL6647166

Cc1ccc(C(=O)Nc2ccc(Cc3ccccn3)cc2)c(N(C)C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.48
KCNB1 Q14721 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.46
RAB9A P51151 5/20 0.46
HPGD P15428 1/20 0.46
NPC1 O15118 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
CTNNB1 P35222 2/20 0.45
TCF7L2 Q9NQB0 2/20 0.45
PLG P00747 3/20 0.44
KLK1 P06870 3/20 0.44
KLK6 Q92876 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPT P10636 1/20 0.43
CYP3A4 P08684 1/20 0.43
KDR P35968 1/20 0.42
HSD17B10 Q99714 1/20 0.42
KEAP1 Q14145 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6647175 0.87 CA1 (0.50) KCNH2KCNB1L3MBTL1RAB9AHPGD
SCHEMBL6647603 0.85 CTNNB1 (0.48) KCNH2KCNB1L3MBTL1RAB9AHPGD
SCHEMBL6649784 0.83 NAMPT (0.53) KCNH2KCNB1L3MBTL1RAB9ANPC1
SCHEMBL6645079 0.82 KMT2A (0.51) L3MBTL1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL6831066 0.81 KCNH2 (0.44) KCNH2KCNB1L3MBTL1RAB9AHPGD
SCHEMBL6644991 0.81 CTNNB1 (0.41) KCNH2KCNB1L3MBTL1RAB9AHPGD
SCHEMBL6643766 0.79 CTNNB1 (0.43) KCNH2KCNB1L3MBTL1RAB9AHPGD
SCHEMBL6788071 0.78 KDM4E (0.51) L3MBTL1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL6644157 0.78 L3MBTL1 (0.41) KCNH2KCNB1L3MBTL1RAB9ANPC1
SCHEMBL6646632 0.78 RAB9A (0.47) KCNH2KCNB1L3MBTL1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR KCNH2 2270/4885KCNB1 444/4885L3MBTL1 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.